Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing Feb 02, 2017
Fortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis Jan 04, 2017
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol Jan 03, 2017
Fortress Biotech Announces Publication on MB‐101 (IL13Rα2‐specific CAR T cells) for the Treatment of Glioblastoma in New England Journal of Medicine Dec 28, 2016
Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology Nov 21, 2016
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights Nov 09, 2016
Fortress Biotech Forms New Subsidiary, Cellvation, Inc., to Develop Novel Therapies for the Treatment of Traumatic Brain Injury Nov 07, 2016
Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne Oct 17, 2016
Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor Oct 03, 2016
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference Sep 23, 2016
